NO20005224L - BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse - Google Patents
BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelseInfo
- Publication number
- NO20005224L NO20005224L NO20005224A NO20005224A NO20005224L NO 20005224 L NO20005224 L NO 20005224L NO 20005224 A NO20005224 A NO 20005224A NO 20005224 A NO20005224 A NO 20005224A NO 20005224 L NO20005224 L NO 20005224L
- Authority
- NO
- Norway
- Prior art keywords
- identification
- methods
- btk inhibitors
- inhibitors
- btk
- Prior art date
Links
- 229940124291 BTK inhibitor Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer BTK inhibitorer, fremgangsmåter for deres identifikasjon og anvendelse, og farmasøytiske sammensetninger som omfatter BTK inhibitorer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8209498P | 1998-04-17 | 1998-04-17 | |
US09/273,191 US6303652B1 (en) | 1998-08-21 | 1999-03-19 | BTK inhibitors and methods for their identification and use |
PCT/US1999/008556 WO1999054286A2 (en) | 1998-04-17 | 1999-04-19 | Btk inhibitors and methods for their identification and use |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20005224D0 NO20005224D0 (no) | 2000-10-17 |
NO20005224L true NO20005224L (no) | 2000-12-18 |
Family
ID=26767041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20005224A NO20005224L (no) | 1998-04-17 | 2000-10-17 | BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1071658B1 (no) |
JP (1) | JP2002512216A (no) |
KR (1) | KR20010042804A (no) |
AT (1) | ATE269295T1 (no) |
AU (1) | AU3653099A (no) |
CA (1) | CA2328962A1 (no) |
DE (1) | DE69918089T2 (no) |
ES (1) | ES2222705T3 (no) |
HU (1) | HUP0102661A2 (no) |
IL (1) | IL139080A0 (no) |
MX (1) | MXPA00010150A (no) |
NO (1) | NO20005224L (no) |
WO (1) | WO1999054286A2 (no) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
AU781986B2 (en) | 1999-11-05 | 2005-06-23 | Cytovia, Inc. | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US6589992B2 (en) | 1999-11-30 | 2003-07-08 | Parker Hughes Institute | Inhibiting collagen-induced platelet aggregation |
WO2001041754A2 (en) * | 1999-11-30 | 2001-06-14 | Parker Hughes Institute | Inhibitors of collagen-induced platelet aggregation |
GB0005345D0 (en) * | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
AU2001236361A1 (en) * | 2000-10-20 | 2002-05-06 | Parker Hughes Institute | Treatment of asthma with lfm analogues |
CA2426508A1 (en) * | 2000-10-23 | 2002-05-16 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
DE60221104T2 (de) * | 2001-03-07 | 2008-03-13 | TELIK, INC., Palo Alto | Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose |
DE10112924A1 (de) * | 2001-03-13 | 2002-10-02 | Erich Eigenbrodt | 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate |
JP4382354B2 (ja) * | 2001-03-13 | 2009-12-09 | ヴァルブルク・グリコムド・ゲーエムベーハー | 1−ブタン酸誘導体およびその使用 |
WO2002092076A1 (en) * | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
JP4593880B2 (ja) | 2001-05-16 | 2010-12-08 | サイトビア インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された4h−クロメンおよび類似体、並びにその使用方法 |
US6858607B1 (en) | 2001-05-16 | 2005-02-22 | Cytovia, Inc. | 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2003027320A2 (en) * | 2001-09-24 | 2003-04-03 | University Of Aarhus | Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1 |
US7476741B2 (en) | 2002-05-16 | 2009-01-13 | Cytovia, Inc. | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
AU2003230411A1 (en) | 2002-05-16 | 2003-12-02 | Cytovia, Inc. | Substituted 4-aryl-4h-pyrrolo(2,3-h)chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2004024676A1 (de) | 2002-09-06 | 2004-03-25 | Schebo®Biotech Ag | Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes |
AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
CN101043883A (zh) * | 2004-10-19 | 2007-09-26 | 安万特药物公司 | (z)-2-氰基-3-羟基-丁-2-烯酸-(4'-三氟甲基苯基)-酰胺用于治疗炎症性肠病的用途 |
JP2010502751A (ja) * | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ,インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
DK2081435T3 (en) | 2006-09-22 | 2016-08-15 | Pharmacyclics Llc | INHIBITORS OF BRUTON'S TYROSINKINASE |
US8232085B2 (en) * | 2007-03-14 | 2012-07-31 | Bionsil S.R.L. | Isoform of bruton's tyrosine kinase (BTK) protein |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
JP5587193B2 (ja) * | 2007-10-23 | 2014-09-10 | エフ.ホフマン−ラ ロシュ アーゲー | 新規なキナーゼ阻害剤 |
WO2009060835A1 (ja) * | 2007-11-05 | 2009-05-14 | Kyoto University | 新規ユビキリン結合性小分子 |
WO2009147624A2 (en) * | 2008-06-05 | 2009-12-10 | Alembic Limited | A process for preparing teriflunomide |
ES2660418T3 (es) | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
CA2795350C (en) * | 2010-04-05 | 2016-02-09 | Mannkind Corporation | Ire-1.alpha. inhibitors |
KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(btk)의 억제제의 용도 |
JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス,インク. | Bruton型チロシンキナーゼの阻害剤 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
CA3218491A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
AU2013344656A1 (en) | 2012-11-15 | 2015-06-04 | Pharmacyclics Llc | Pyrrolopyrimidine compounds as kinase inhibitors |
CN105189737B (zh) * | 2012-11-28 | 2019-02-12 | 康宁股份有限公司 | 用于增强肝细胞功能的细胞培养基 |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
EP2981264B1 (en) | 2013-04-02 | 2018-04-25 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
EP2832358A1 (en) * | 2013-08-02 | 2015-02-04 | Bionsil S.r.l. | Pharmaceutical kit for use in the treatment of colon and colorectal cancer |
JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
PE20160560A1 (es) | 2013-09-30 | 2016-06-09 | Pharmacyclics Llc | DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK) |
JP6878004B2 (ja) | 2013-12-13 | 2021-05-26 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
CN105272882B (zh) * | 2014-07-23 | 2019-05-31 | 欣凯医药化工中间体(上海)有限公司 | 一种环保简便制备泰瑞米特的方法 |
WO2016019233A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
MX2017001671A (es) | 2014-08-07 | 2017-07-04 | Pharmacyclics Llc | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. |
EP3209648B1 (en) | 2014-10-22 | 2020-03-11 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
BR122023020985A2 (pt) | 2015-03-03 | 2023-12-26 | Pharmacyclics Llc | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton |
WO2017173111A1 (en) | 2016-03-31 | 2017-10-05 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2555685A1 (de) * | 1975-12-11 | 1977-06-23 | Hoechst Ag | Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
BR9008022A (pt) * | 1990-05-18 | 1993-04-06 | Hoechst Ag | Amida de acido isoxazol-4-carboxilico e amidas de acido hidroxialquilideno-cianoacetico,medicamentos contendo estes compostos e sua aplicacao |
CA2080554A1 (en) * | 1991-10-15 | 1993-04-16 | Mitsubishi Chemical Corporation | Styrene derivatives |
GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
EP0674643A1 (en) * | 1992-12-23 | 1995-10-04 | Smithkline Beecham Corporation | Coumarin derivatives as retroviral inhibitors |
GB9322781D0 (en) * | 1993-11-04 | 1993-12-22 | Roussel Lab Ltd | Aromatic amides |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US5489697A (en) * | 1994-08-03 | 1996-02-06 | Medichem Research, Inc. | Method for the preparation of (+)-calanolide A and intermediates thereof |
US5608085A (en) * | 1995-02-27 | 1997-03-04 | The University Of Tennessee Research Corporation | Synthesis of optically active calanolides A and B and enantiomers and related compounds |
WO1996031206A2 (en) * | 1995-04-07 | 1996-10-10 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of atherosclerosis |
IT1289238B1 (it) * | 1996-12-10 | 1998-09-29 | Bio S S P A Ora Bio S S R L | Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina |
-
1999
- 1999-04-19 MX MXPA00010150A patent/MXPA00010150A/es unknown
- 1999-04-19 IL IL13908099A patent/IL139080A0/xx unknown
- 1999-04-19 AT AT99918673T patent/ATE269295T1/de not_active IP Right Cessation
- 1999-04-19 KR KR1020007011551A patent/KR20010042804A/ko not_active Application Discontinuation
- 1999-04-19 DE DE69918089T patent/DE69918089T2/de not_active Expired - Fee Related
- 1999-04-19 CA CA002328962A patent/CA2328962A1/en not_active Abandoned
- 1999-04-19 JP JP2000544627A patent/JP2002512216A/ja active Pending
- 1999-04-19 AU AU36530/99A patent/AU3653099A/en not_active Abandoned
- 1999-04-19 EP EP99918673A patent/EP1071658B1/en not_active Expired - Lifetime
- 1999-04-19 HU HU0102661A patent/HUP0102661A2/hu unknown
- 1999-04-19 ES ES99918673T patent/ES2222705T3/es not_active Expired - Lifetime
- 1999-04-19 WO PCT/US1999/008556 patent/WO1999054286A2/en not_active Application Discontinuation
-
2000
- 2000-10-17 NO NO20005224A patent/NO20005224L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL139080A0 (en) | 2001-11-25 |
WO1999054286A2 (en) | 1999-10-28 |
CA2328962A1 (en) | 1999-10-28 |
ES2222705T3 (es) | 2005-02-01 |
JP2002512216A (ja) | 2002-04-23 |
DE69918089D1 (de) | 2004-07-22 |
ATE269295T1 (de) | 2004-07-15 |
EP1071658B1 (en) | 2004-06-16 |
WO1999054286A3 (en) | 2000-05-04 |
MXPA00010150A (es) | 2002-05-14 |
NO20005224D0 (no) | 2000-10-17 |
DE69918089T2 (de) | 2005-07-14 |
HUP0102661A2 (hu) | 2001-11-28 |
EP1071658A2 (en) | 2001-01-31 |
KR20010042804A (ko) | 2001-05-25 |
AU3653099A (en) | 1999-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20005224L (no) | BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse | |
DE60007095D1 (de) | Calanolide zur hemmung von btk | |
TR200100054T2 (tr) | Paroksetin metansülfonat | |
CY1112687T1 (el) | Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες | |
DK1355889T3 (da) | Substituerede triazoldiaminderivater som kinaseinhibitorer | |
TR200002480T2 (tr) | İzaşemi tedavisi için guanidin türevleri | |
TR200202194T2 (tr) | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri | |
BR0317715A (pt) | Composições e processos de uso de collajolie | |
PT1202724E (pt) | Metodo para tratamento da dor cronica utilizando inibidores mek | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
ATE289640T1 (de) | Amidofunktionelle aminopolydiorganosiloxane | |
DK1114032T3 (da) | 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer | |
NO20053356D0 (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
BR0215405A (pt) | Composições e processos de uso de collajolie | |
ATE231872T1 (de) | Thiazolopyrimidinderivate | |
DK1086082T3 (da) | Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister | |
DK1097173T3 (da) | Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler | |
DK1322158T3 (da) | Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf | |
NO980178L (no) | Cyklo-oksygenase-inhibitor og amidin-derivatsalter, fremgangsmåte for fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende slike derivater | |
NO20041432L (no) | Sammensetninger som innbefatter COX-2 inhibitorer og aspirin. | |
NO20013853D0 (no) | Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer | |
NO20060065L (no) | Tabletter inneholdende enrofloksacin og smaks- og/eller aromastoffer | |
DK1214302T3 (da) | Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere | |
NO20033921L (no) | Inhibitor av monoaminopptak | |
NO995945L (no) | Nye forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |